Effectiveness and safety of dupilumab for the treatment of severe asthma in a real-life French multi-centre adult cohort.
Fiche publication
Date publication
mai 2020
Journal
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BONNIAUD Philippe
Tous les auteurs :
Dupin C, Belhadi D, Guilleminault L, Gamez AS, Berger P, De Blay F, Bonniaud P, Leroyer C, Mahay G, Girodet PO, Raherison C, Fry S, Le Bourdellès G, Proust A, Rosencher L, Garcia G, Bourdin A, Chenivesse C, Didier A, Couffignal C, Taillé C
Lien Pubmed
Résumé
Dupilumab is a monoclonal anti-IL-4Rα antibody developed for the treatment of severe asthma (SA). An early access programme for dupilumab was opened in France in SA patients experiencing unacceptable steroids side-effects and/or life-threatening exacerbations.
Mots clés
T2 inflammation, asthma, hypereosinophilia, oral steroid, side-effect
Référence
Clin. Exp. Allergy. 2020 May 29;: